PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Androgen deficiency in aging men
Article published in Urologia Polska 2002/55/4.

authors

Andrzej Gomuła
Klinika Urologii Instytutu Chirurgii Centralnego Szpitala Klinicznego Wojskowej Akademii Medycznej w Warszawie Kierownik Kliniki: prof, dr hab. Henryk Zieliński

keywords

testis, testosterone deficiency, androgen substitutional therapy, endogenous testosterone synthesis

summary

Androgens play a very important role in men. Its activity decides on sexual differentiation, structure and function of the brain. Testosterone (T) controls processes of the synthesis on cellular level. High levels of the testosterone makes possible to main-te-nance of good physical and psychical conditions. Such symptoms as osseous mineralization, muscular strenght, body pilosity, erythropoesis, proteins, lipids and carbohydrates metabolism, or spermiogencsis arc strictly related to testosterone. It also influences on personality and sexual behavior of man. In old men serum testosterone level decreases, that may be a cause of metabolic disorders and development of some diseases.
This study presents our actual knowledge on the role of T in a man\'s life and the results of T deficiency, according to directives of ISSAM, review of the literature and own experience. The methods of increasing T levels by preparats of T and Lcydig cells stimulation to return own T synthesis of the host have been also presented.

references

  1. 1. Gooren LIG: Qualily-of-life issues in the aging male. Aging Male 2000; 3:185-189.
  2. 2. Loran OB, Segal AS: fOimakteiicheskye rasstroistva u mushehin. Moscow 1999.
  3. 3. Lunenfeld B: Testosterone supplementation: Sense or Nonsense. V Zjazd Polskiego Towarzystwa Manopauzy i Andropauzy, 30.11-2.12.2000, Warszawa; 100-105.
  4. 4. www.andropause.com - Canadian Andropause Society.
  5. 5. Gertig T Dojrzewanie płciowe i jego zabuizenia; w: Podstawy endokrynologii wieku rozwojowego, PZWL, Warszawa, 1999.
  6. 6. Greene R: Sex steroids and brain functioning in the aging male. Aging Male 2001; 4: 39-43.
  7. 7. Korenman SG, Morley JE, Mooradian AD et al: Secondary hypogonadism in older men: its relationships to impotence. I Clin Endocrinol Metab 1990; 71: 963-969.
  8. 8. Gooren LIG: Visceral obesity, androgens and the risk of cardiova scalar disease and diabetes mellitus. Aging Male 2001; 4: 30-38.
  9. 9. Marin P, Holmang S, Gustai\\\\\\\'sson el al: Tlie effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Inl J of Obesity 1992; 16: 991-997.
  10. 10. Matsumoto AM, Marck BX Gmenenwald DA Wolden-Hanson T, Naai MA: Aging and the newoendocrine regulation of reproduction and body weight. Exp Gerontol 2000; 35: 1251-1265.
  11. 11. Resnick 1 IE: Epidemiological aspects of diabetes in the aging male. Aging Male 2000; 3: 96-105.
  12. 12. Morales A, Lunenfeld B: Investigation, treatment band monitoring of late-onset hypogonadism In males. Oficial recomendations oflS-SAM. Aging Male 2002; 5: 74-86.
  13. 13. Tan R, Bransgrove L: Testosterone replacement therapy. Postgraduate Medicine 1998; 103: 247-252.
  14. 14. Lunenfeld B: Hormone replacement in the aging male (editorial). The Aging Male 1999; 2: 1-5.
  15. 15. Pollard M: Dihydroteslosterone prevents spontaneous adenocarcinomas in the prostate-seminal vesicle in aging L-W rats. Prostae 1998; 36:168-171.
  16. 16. Vermeulen A: The future of hormone replacement therapy in the aging male. Aging Male Symposium. Tlie 2nd World Congress on the Aging Male. Geneva 2000.
  17. 17. Crook D: Androgens and the risk of cardiovascular disease. Aging Male Symposium. The 2nd Worid Congress on the Aging Male. Geneva 2000.
  18. 18. Gomula A: The influence of chorionic gonadotropin on endogenic testosterone synthesis. Aging Male, 2001; 4: 85.
  19. 19. Reiter WJ, Mock K, Lunglmayr G, Kratzik Ch: Oral dehyroepian-drosterone in erectal dysfunction. A three year experience. The Aging Male 2000, 3: 35.
  20. 20. Morales A: Aging band urology: growing together in the new century. SIU Congress Newsletter. Sept. 10,2(K)2, p. 2.
  21. 21. Vermeulen A: Some reflections on the endocrinology of the aging male. Aging Male 1998; 1:163-168.
  22. 22. Comhaire FH: Hormone replacement therapy in the aging male. Euv Urol 2000; 38: 665-662.
  23. 23. Morales A, Lunenfeld B: Androgen replacement therapy In aging men with secondary hypogonadism. Aging Male 2002; 4:151-162.
  24. 24. Ferrini RL, Barrett-Connor E: Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol 1998; 147: 750-754.
  25. 25. Novolodskaya JV: MIU size of hypophysis of erderfy men. Aging Male, 2001; 4:248.
  26. 26. Mosby\\\\\\\'s Medical, Nursing and Allied Health Dictionary. 5th ed, Mosby, 1998, USA.
  27. 27. Cunninhgam GR: Management of male aging: which testosterone replacement therapy should be used? Aging Male, 2000,3:203-209.
  28. 28. Ferenz T: Hormonalne aspekty etiopatogenezy i leczenia łagodnego rozrostu gruczoht krokowego. Farmacja Polska 1998; 54, 17: 778-781.
  29. 29. Hartnell J, Korenman SG, Viosca SP: Results of testosterone enen-thatc therapy for hypogonadism in older men. Proceedings of the 72nd Annual Meeting of the Endocrine Society 1990, June: 428.
  30. 30. Tcnovcr JS: Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75:1092-1098.
  31. 31. Harbitz TB, Haugen OA: Endocrine disturbances in men with benign hyperplasia and carcinoma oftheprostatae. Acta Path Microbiol Scand 1974; 244, suppl 1.
  32. 32. Horton RPI wsp: Altered blood androgens in elderly men with prostate Shypeiplasia. J Clin Endocrinol Metab 1975; 41: 793.
  33. 33. Zgliczynski S: Andropauza - 2000. Przegl Urol 2000; 2: 54-57.
  34. 34. Pharmindex, 1999/2, MediMedia Int, Warsaw, 1999; L-66.
  35. 35. Perdzyński W: Moje doświadczenia w leczeniu preparatem Biogona-dyl - u autora.
  36. 36. Rymkiewicz-Kluczyńska B: Moje doświadczenia w leczeniu preparatem Biogonadyl - u autora.
  37. 37. Szymkiewicz Cz: Moje doświadczenia w leczeniu preparatem Biogonadyl - u autora.
  38. 38. Raport z dnia 14.11. 2000 Centtum Farmakoepidemiologii - Ośrodka Monitorowaniu Niepożądanych Działań Leków Instytutu Leków w Warszawie - u autora.
  39. 39. Gooren L: A ten years safety study of the oral androgen testosterone undecanoale. J Androl 1994; 15: 212-215.
  40. 40. Gooren LJG: Options of androgen treatment in the aging male. Aging Male 1999; 2: 73-80.
  41. 41. Marin P, Holmang S, Gustafsson el al: The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J of Obesity 1992; 16: 991-997.
  42. 42. Tenover JL: Testosterone and the aging male. J Androl 1997; 18: 103-106.
  43. 43. Hartwig W: Endokrynologia, Warszawa, PZWL, 1978; str. 767.
  44. 44. Bernini GP, Argenio GF, Gasperi M, Vivaldi MS, Franchi F, Sa-lvetti A: Effects of long-term simvastatin treatment on testicular and adrenal steroidogenesis in hypercholesterolemic patients. J-Endocri-nol-Invest 1994; 17: 227-233.
  45. 45. Mostofi F K: Carcinoma oftheprostatae. w: Modem trends in urology - 3, Butterwortlis, London 1970, str. 231-263.
  46. 46. Walanabe M, Fukulomc K, Kato H, Murata M, Kawamura J, Shi-raishi I, Yatani R: I\\\\\\\'rogresion-linked overexprcsion ofc-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. Cancer Lett 1999; 141:173-178.
  47. 47. Slowikowska-Ililczcr J. Kula K: Odgonocyla do raka jadra. Przcgi Urol 2000; 4,38-41.
  48. 48. Kaufman JM, Zmierczak H, Goemaere S: Osteoporosis in the aging population: the male perspective. Aging Male, 2000; 4: 62-73.
  49. 49. Collinson MP, Tyrrell CJ, Hutton C: Osteoporosis occurring in two patients receiving LHRHanalogs for carcinoma of the prostate. Calif Tissue Int, 1994; 54: 327-328.
  50. 50. Hatano T, Oishi Y, Furuta A el al: Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonist for prostate cancer. BJU Int 2000; 86: 449-452.

correspondence

Andrzej Gomula
Klinika Urologii Centralnego Szpitala Klinicznego WAM
ul. Szaserów 128
00-900 Warszawa